We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+10.26%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$9.11B
AUM Growth
+$430M
Cap. Flow
-$417M
Cap. Flow %
-4.58%
Top 10 Hldgs %
48.86%
Holding
90
New
18
Increased
24
Reduced
16
Closed
18

Sector Composition

Rank Sector Weight
1 Communication Services 22.15%
2 Technology 15.42%
3 Healthcare 12.02%
4 Industrials 8.8%
5 Consumer Staples 7.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AKAO
51
DELISTED
Achaogen Inc
AKAO
$20.6M 0.23%
817,500
+467,500
+134% +$9.6M
GRFS
52
Grifois
GRFS
$5.36B
$20.4M 0.22%
1,079,874
KYNB
53
Kyntra Bio
KYNB
$27.2M
$16.8M 0.18%
27,280
-4,000
-13% -$2.44M
RYAAY icon
54
Ryanair
RYAAY
$30.4B
$15.2M 0.17%
+459,288
New +$15.2M
PTLA
55
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$15.1M 0.17%
385,000
+285,000
+285% +$9.08M
CLUB
56
DELISTED
Town Sports International Holdings, Inc.
CLUB
$14.4M 0.16%
4,060,082
LKFT
57
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$10.3M 0.11%
120,000
+29,045
+32% +$2.09M
NVET
58
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$10.3M 0.11%
2,648,696
STML
59
DELISTED
Stemline Therapeutics, Inc.
STML
$9.98M 0.11%
1,167,500
+910,000
+353% +$8.29M
LJPC
60
DELISTED
La Jolla Pharmaceutical Company
LJPC
$7.69M 0.08%
+257,500
New +$6.57M
PCO
61
DELISTED
Pendrell Corporation - Class A
PCO
$5.34M 0.06%
8,211
CLVS
62
DELISTED
Clovis Oncology, Inc.
CLVS
$5.09M 0.06%
+80,000
New +$4.86M
KATE
63
DELISTED
Kate Spade & Company
KATE
$4.88M 0.05%
+210,000
New +$4.39M
AMRN
64
Amarin Corp
AMRN
$299M
$4.78M 0.05%
74,750
-30,500
-29% -$1.94M
ALR
65
CALL
DELISTED
Alere Inc
ALR
$3.26M 0.04%
+82,000
New +$3.2M
ACRS icon
66
Aclaris Therapeutics
ACRS
$726M
$3.19M 0.04%
+106,894
New +$3.08M
GCVRZ
67
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$3.07M 0.03%
6,827,805
MITL
68
DELISTED
Mitel Networks Corporation
MITL
$2.68M 0.03%
386,267
ABBV icon
69
AbbVie
ABBV
$443B
-160,000
Closed -$10M
BCE icon
70
BCE
BCE
$20.2B
-133,650
Closed -$5.78M
GILD icon
71
Gilead Sciences
GILD
$162B
-135,000
Closed -$9.67M
HPP
72
Hudson Pacific Properties
HPP
$747M
-165,703
Closed -$40.3M
ILMN icon
73
Illumina
ILMN
$31B
-19,532
Closed -$2.43M
LILA icon
74
Liberty Latin America Class A
LILA
$1.64B
-1,848,120
Closed -$26M
SPY icon
75
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$790B
-7,080,000
Closed -$1.58B

Similar funds

Farallon Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Farallon Capital Management held 90 positions worth $9.11B, up 5% from $8.68B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Farallon Capital Management withdrew a net $417M in Q1 2017, closing 18 positions and reducing 16 holdings. Its most notable exit was St Jude Medical, an estimated $712M position sold in full.

By sector, the portfolio is most concentrated in Communication Services at 22% of assets, up from 14% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Farallon Capital Management opened a new position in Meta Platforms (Facebook) worth $367M.

  • Farallon Capital Management's largest Q1 2017 buy was Meta Platforms (Facebook): 2,583,043 shares worth $367M.
  • Farallon Capital Management added most to Yahoo Inc in Q1 2017, an estimated $394M increase.
  • Farallon Capital Management's biggest Q1 2017 reduction was Corpay, cutting an estimated $189M.
  • Farallon Capital Management fully exited St Jude Medical in Q1 2017, selling an estimated $712M.
  • Farallon Capital Management's ten largest holdings make up 49% of its $9.11B portfolio in Q1 2017.
  • Farallon Capital Management opened 18 new positions and closed 18 in Q1 2017.
  • Farallon Capital Management's portfolio value rose 5% quarter-over-quarter to $9.11B.

Based on Farallon Capital Management's 13F filing for Q1 2017, filed 15 May 2017.